We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rare Non-Neuroendocrine Pancreatic Tumours.
- Authors
Mormul, Agata; Włoszek, Emilia; Nowoszewska, Julia; Fudalej, Marta; Budzik, Michał; Badowska-Kozakiewicz, Anna; Deptała, Andrzej
- Abstract
Simple Summary: Pancreatic ductal adenocarcinoma accounts for 85% of non-neuroendocrine pancreatic lesions. The remaining 15% consists of numerous diverse neoplasms, both malignant and benign. We gathered the latest data about the epidemiology, diagnosis, biomarkers and management of six rare pancreatic tumours: intraductal papillary mucinous neoplasm, mucinous cystadenoma, serous cystic neoplasm, acinar cell carcinoma, solid pseudopapillary neoplasm and pancreatoblastoma. Frequent guideline updates can help to avoid misdiagnosis, which could lead to unnecessary resections or oversight of malignant transformations. The most common tumour of the pancreas is ductal adenocarcinoma (PDAC). It remains one of the most lethal non-neuroendocrine solid tumours despite the use of a multi-approach strategy. Other, less-common neoplasms, which are responsible for 15% of pancreatic lesions, differ in treatment and prognosis. Due to the low incidence rate, there is a lack of information about the rarest pancreatic tumours. In this review, we described six rare pancreatic tumours: intraductal papillary mucinous neoplasm (IPMN), mucinous cystadenoma (MCN), serous cystic neoplasm (SCN), acinar cell carcinoma (ACC), solid pseudopapillary neoplasm (SPN) and pancreatoblastoma (PB). We distinguished their epidemiology, clinical and gross features, covered the newest reports about courses of treatment and systematised differential diagnoses. Although the most common pancreatic tumour, PDAC, has the highest malignant potential, it is still essential to properly classify and differentiate less-common lesions. It is vital to continue the search for new biomarkers, genetic mutations and the development of more specific biochemical tests for determining malignancy in rare pancreatic neoplasms.
- Subjects
PANCREATIC tumors; BIOMARKERS; GENETIC mutation; PAPILLARY carcinoma; DIFFERENTIAL diagnosis; NEUROENDOCRINE tumors; TUMORS; RARE diseases
- Publication
Cancers, 2023, Vol 15, Issue 8, p2216
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers15082216